2225 Colorado Avenue
About Kite Pharma
Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development.
For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
With an unrelenting drive and a singular focus on cell therapy, our team is executing on our strategy to bring life-saving therapies to patients.
250 articles with Kite Pharma
European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
-- If Approved, KTE-X19 will be an Important New Advance for this Disease with a Poor Prognosis -- -- Kite would Become the First Company with Multiple Approved CAR T Therapies in Europe -- SANTA MONICA, Calif.--( BUSINESS WIRE )-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s Marketing Auth
10/6/2020According to BioSpace research, 69% of biotech professionals feel they are on the verge of job burnout. Do you fall into that 69%? Is it time for a new job? Check out the top companies who are looking for candidates like you right now!
Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia
Research Collaboration will Leverage HiFiBiO’s Proprietary Single-Cell Platform to Identify Novel Targets to Support Kite’s Development of Cell Therapies in AML -- SANTA MONICA, Calif. & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML). Through this collaboratio
Maryland has become a key part of the strategy for Kite, a Gilead company, and its mission to find a cure for cancer.
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
The U.S. Food and Drug Administration (FDA) approved Kite Pharma’s Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). Kite is a Gilead Science company.
Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe
Amsterdam Facility will Bring Kite’s Potentially Life-Saving Individualized Treatment Closer to People with Advanced Blood Cancers in the European Region --
Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Yescarta ® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma -- 93 Percent of Patients with Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma Responded to a Single Infusion of Yescarta, with 80 Percent Achieving a Complete Response -- -- Data Presented in an Oral Session During the 2020 American Society of Clinical Oncology Annual Meeting --
Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting
Nine Abstracts, Including Three Oral Presentations, Highlight Leadership in Hematologic Malignancies and Early Progress in Solid Tumors
The goal is to support the discovery and development of next-generation drug and engineered cell therapies, specifically with a focus on natural killer (NK) cells.
Kite and Teneobio will Collaborate on Next-Generation Dual-Targeting CAR T Therapies in Multiple Myeloma Utilizing UniAb® Antibodies
Arie Belldegrun, the co-founder and executive chairman of the board of Allogene, disclosed this weekend that he has been diagnosed with COVID-19. The pharma entrepreneur is in self-quarantine and is doing well.
A number of new medications stand a shot at early regulatory approval thanks to the U.S. Food and Drug Administration’s priority review program.
U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma
Feb. 10, 2020 13:30 UTC -- If Approved, Kite Could be First Company with Multiple Commercialized CAR T Therapies -- SANTA MONICA, Calif.--( BUSINESS WIRE )-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with r
European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell Therapy
Investigational KTE-X19 To Be First Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma in Europe if Approved
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta
Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy
Investigational KTE-X19 To Be First Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma if Approved
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter ended September 30, 2019.
Mr. Dickinson joined Gilead in 2016 and has transformed the way that the company approaches corporate development, expanding the kinds of transactions executed and implementing a broader and more strategic approach to deal-making.
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in t...